 Due to the FDA uncertainty, TG Therapeutics shares took a big hit earlier this month. Nevertheless, the stock is showing signs of a rebound going into Fiscal 2022. The upcoming U2 approval for chronic lymphocytic leukemia and small lymphocytic lymphoma is a crucial development. 